Edition:
United States

People: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

62.73USD
24 Aug 2016
Change (% chg)

-- (--)
Prev Close
$62.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,872,963
52-wk High
$64.00
52-wk Low
$45.70

Perlmutter, Roger 

Dr. Roger M. Perlmutter, M.D., Ph.D., is Executive Vice President, President - Merck Research Laboratories of Merck & Co Inc. effective April 15, 2013. He is responsible for the Company’s global research and development efforts. Dr. Perlmutter was executive vice president and head of R&D at Amgen Inc. from January 2001 to February 2012. During his tenure, Dr. Perlmutter oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis. Prior to joining Amgen, he was executive vice president of worldwide basic research and preclinical development at Merck. He joined Merck as a senior vice president in February 1997. Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, where he also served as chairman of the Department of Immunology and was a Howard Hughes Medical Institute investigator. He is a Fellow of the American Academy of Arts and Sciences and an elected Fellow of the American Association for the Advancement of Science. Dr. Perlmutter graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University in St. Louis in 1979.

Basic Compensation

Total Annual Compensation, USD 2,968,630
Restricted Stock Awards, USD 3,335,960
Long-Term Incentive Plans, USD --
All Other, USD 1,996,670
Fiscal Year Total, USD 8,301,260

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --